OncoCyte (NAS:OCX) Enterprise Value

: $17.56 Mil (As of Today)

View and export this data going back to 2015. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, OncoCyte's Enterprise Value is $17.56 Mil. OncoCyte's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-63.61 Mil. Therefore, OncoCyte's EV-to-EBIT ratio for today is -0.28.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, OncoCyte's Enterprise Value is $17.56 Mil. OncoCyte's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-58.41 Mil. Therefore, OncoCyte's EV-to-EBITDA ratio for today is -0.30.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, OncoCyte's Enterprise Value is $17.56 Mil. OncoCyte's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $8.10 Mil. Therefore, OncoCyte's EV-to-Revenue ratio for today is 2.17.

OncoCyte Enterprise Value Historical Data

The historical data trend for OncoCyte's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Enterprise Value

140.39

49.37

111.81

166.00

169.31

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Enterprise Value																290.05	169.31	121.58	70.70	57.88

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

OncoCyte Enterprise Value Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Enterprise Value distribution charts can be found below:

* The bar in red indicates where OncoCyte's Enterprise Value falls in comparison to its industry or sector. The grey bar indicates the Enterprise Value's extreme value range as defined by GuruFocus.

OncoCyte Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

OncoCyte's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as

	Enterprise Value (A: Dec. 2021 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	200.143223	+	0	+	3.545
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	2.132	+	0	-	36.509
=	169.31

OncoCyte's Enterprise Value for the quarter that ended in Sep. 2022 is calculated as

	Enterprise Value (Q: Sep. 2022 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	86.59187	+	0	+	2.935
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0.827	+	0	-	32.472
=	57.88

OncoCyte (NAS:OCX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

OncoCyte's EV-to-EBIT for today is

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	17.561	/	-63.605
	=	-0.28

OncoCyte's current Enterprise Value is $17.56 Mil.
OncoCyte's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.61 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

OncoCyte's EV-to-EBITDA for today is:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA(TTM)
	=	17.561	/	-58.411
	=	-0.30

OncoCyte's current Enterprise Value is $17.56 Mil.
OncoCyte's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.41 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

OncoCyte's EV-to-Revenue for today is:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	17.561	/	8.097
	=	2.17

OncoCyte's current Enterprise Value is $17.56 Mil.
OncoCyte's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.10 Mil.

OncoCyte Enterprise Value Related Terms

Thank you for viewing the detailed overview of OncoCyte's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » Enterprise Value

Comparable Companies

Traded in Other Exchanges

7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund	director	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen	officer: Chief Operating Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross	officer: Chief Medical Officer	15 CUSHING, IRVINE CA 92618
Tony T Kalajian	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008